Meiji Seika Pharma has announced its investment in ARCALIS, a joint venture focused on the development and manufacturing of mRNA vaccines and pharmaceuticals. This collaboration aims to bolster the production of mRNA vaccines in Japan, ensuring faster and more reliable
WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced plans to enhance its drug product (DP) capabilities at its Leverkusen, Germany facility. The company will add a new sterile filling line for prefilled syringes (PFS) using
SpectronRx has signed a commercial supply agreement with Cellectar Biosciences, Inc. to manufacture iopofosine I 131, a promising first-in-class cancer therapy. This agreement marks a significant step in the development and global distribution of the drug, which has shown efficacy
DINAMIQS, part of the Siegfried group, has inaugurated advanced research and development laboratories in Zurich, Switzerland. The newly expanded facilities aim to bolster the company’s offering in the fast-growing cell and gene therapy market. These laboratories will house cutting-edge technologies
Nutcracker Therapeutics, a biotechnology company known for its proprietary RNA technology platform, has announced new contract research, development, and manufacturing organization (CRDMO) capabilities. The company’s expansion aims to provide scalable, flexible solutions to support RNA drug developers from early discovery
SyVento Biotech, a contract development and manufacturing organisation (CDMO), has announced the opening of its new mRNA manufacturing facility in Poland. This state-of-the-art site, spanning over 7,000 m², includes lab and production areas, offices, and shared spaces. It marks a
Affinia Therapeutics and Forge Biologics have announced a partnership to transfer technology and produce clinical trial material for Affinia’s gene therapy programs under Current Good Manufacturing Practice (cGMP) standards. The agreement covers Affinia’s investigational treatment AFTX-201, developed to target BAG3
Reverb Therapeutics has announced a collaboration with Montreal-based Royalmount Laboratories to support pre-IND enabling work on Reverb’s lead drug candidate, which is currently moving towards lead selection. The partnership will focus on critical bioanalytical and development tasks to prepare for
“The reality is, we have a lot of CDMOs that don’t really know what they’re getting into” says Herman Bozenhardt Herman Bozenhardt, a pharmaceutical manufacturing consultant with decades of experience in facility design and operations, brings a wealth of knowledge
Asymchem has reached a new milestone in pharmaceutical contract manufacturing with the introduction of fully automated, large-scale peptide drug production. This achievement, accomplished through advanced engineering and system integration, addresses several industry challenges in scaling up chemical macromolecule synthesis. Asymchem’s
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
